NexPoint Strategic Opportunities Fund
Change company Symbol lookup
Select an option...
NHF NexPoint Strategic Opportunities Fund
FUAPF Global Cannabis Applications Corp
GXG Global X MSCI Colombia ETF
ATMR Altimar Acquisition Corp II
AMD Advanced Micro Devices Inc
WST West Pharmaceutical Services Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp

Company profile

NexPoint Strategic Opportunities Fund (the Trust), formerly NexPoint Credit Strategies Fund, is a non-diversified, closed-end management investment company. The Trust's objective is to provide both current income and capital appreciation. The Trust allocates its investments in public equities, private equity investments, collateralized loan obligation (CLOs) debt, high yield bonds, syndicated floating rate bank loans, real estate assets, CLO equity, non-traditional yield oriented investments and hedge exposure where necessary. The Trust invests in various sectors, which include chemicals, energy, gaming and leisure, housing, media and telecommunications, real estate investment trust, healthcare, asset-backed securities, and information technology. NexPoint Advisers L.P. serves as the investment adviser to the Trust.

Closing Price
Day's Change
-0.17 (-1.18%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Pfizer cites 'totality' of clinical data in bid for COVID-19 booster approval

9:29 am ET September 15, 2021 (MarketWatch)

Shares of Pfizer Inc. (PFE) gained 0.1% in premarket trading on Wednesday after the drug maker said the "totality" of clinical data indicates that people who are at least 16 years old and were vaccinated with the COVID-19 shot that it developed with BioNTech SE (BNTX) should get a booster after six months. In a document published Wednesday morning by the Food and Drug Administration in advance of an advisory committee meeting set for Friday, Pfizer said its Phase 3 substudy examined 306 people between the ages of 18 and 55 years old who got a third dose. It found that an extra dose is considered safe and increased neutralizing antibody titers against the original strain of the virus as well as the beta and delta variants to a higher rate than what was reported after two doses in the clinical trials last year. Younger participants were more likely to report systemic events after the second and third doses than the first dose; fever was more common after the third dose. No adverse events were reported in the first month after the third dose. Pfizer also cited research conducted by Israel, the Centers for Disease Control and Prevention, and the hospital system Kaiser Permanente in the document, saying that data from Israel "suggest reduced effectiveness against severe disease could eventually follow observed reductions in effectiveness against SARS-CoV-2 infections." Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%.

-Jaimy Lee


(END) Dow Jones Newswires

September 15, 2021 09:29 ET (13:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.